Search Results
Your search for ,aLl matches 18308 pages
Showing 1951 - 2000Novel Molecular Twin Tool May Improve Precision Medicine Care in Patients With Pancreatic Cancer
The novel artificial intelligence (AI)-based Molecular Twin Precision Oncology Platform may be capable of identifying biomarkers that may outperform the standard test for predicting pancreatic cancer survival, according to a recent study published by Osipov et al in Nature Cancer. Background...
Beyond Lung Cancer: Leveraging Machine Learning Techniques to Understand Other Diseases
Although computed tomography (CT) screening has emerged as an essential tool for the early detection of lung diseases, there is still a broad range of potential improvements to be made. According to recent research, understanding the patterns of onset for earlier prediction of disease may be...
Tackling the Challenges of Oncology Workforce Shortages, Increased Patient Demand, and Rising Costs of Care
In May 2023, The ASCO Post launched a new feature, View From the Top: The Future of Cancer Care Delivery, which explores how leaders in oncology are developing strategies to ensure continued innovative oncology care in an ever-changing health-care environment. In this installment, Guest Editor Jame ...
NETTER-2: Lu-177 Dotatate for Advanced Gastroenteropancreatic Neuroendocrine Tumors
Results from the first phase III clinical trial evaluating radioligand therapy in the first-line setting demonstrated that treatment with lutetium Lu-177 dotatate significantly improved progression-free survival and objective response rates in patients with high-grade gastroenteropancreatic...
Standard vs Histology-Tailored Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma
In an expanded cohort of a European trial reported in the Journal of Clinical Oncology, Alessandro Gronchi, MD, and colleagues found that histology-tailored neoadjuvant chemotherapy with trabectedin was noninferior in terms of disease-free survival to standard neoadjuvant anthracycline/ifosfamide...
Addition of Cetuximab Maintenance to First-Line FOLFIRI/Cetuximab in RAS/BRAF Wild-Type Colorectal Cancer
As reported in the Journal of Clinical Oncology by Pinto et al, the Italian phase III ERMES trial showed that the addition of cetuximab maintenance to eight cycles of first-line FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus cetuximab did not achieve noninferiority in terms of...
Novel PI3K Inhibitor as Part of Triplet Improves Outcomes in Hormone Receptor–Positive, HER2-Negative Breast Cancer
The addition of inavolisib to first-line treatment with palbociclib plus fulvestrant more than doubled progression-free survival in patients with recurrent PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer, according to a late-breaking primary analysis of the phase III ...
Normal Risk Ovarian Screening Study: Long-Term Update
As reported in the Journal of Clinical Oncology by Han et al, the 21-year update of the Normal Risk Ovarian Screening Study (NROSS) has shown that the NROSS screening strategy remains effective for the detection of ovarian cancer and detection at early disease stages. Study Details The NROSS...
Undocumented Cost-of-Care Discussions: A Missed Opportunity in Cancer Treatment
A recent study underscored the need for integrating cost-of-care conversations in cancer treatment. Results of the population-based analysis, presented at the 2023 ASCO Quality Care Symposium,1 showed that only about 25% of patients with newly diagnosed advanced non–small cell lung cancer (NSCLC)...
MRD Status and Outcomes With Obinutuzumab- and Rituximab-Based Treatment in Follicular Lymphoma
In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD) status and related outcomes among patients receiving obinutuzumab- and rituximab-based treatment for previously untreated follicular lymphoma. Study...
Harinder Gill, MD, MBBS, on Acute Promyelocytic Leukemia: Assessing the Use of Oral Arsenic Trioxide, Retinoic Acid, and Ascorbic Acid
Harinder Gill, MD, MBBS, of The University of Hong Kong, discusses findings showing the use of an “AAA” regimen (pure oral arsenic trioxide combined with all-trans retinoic acid) in a risk-adapted strategy that minimized chemotherapy was highly effective and safe in patients with newly diagnosed...
Jeffrey E. Rubnitz, MD, PhD, on Pediatric AML Outcomes and Racial Disparities
Jeffrey E. Rubnitz, MD, PhD, of St. Jude Children’s Research Hospital, discusses study findings suggesting that pharmacogenomic differences between Black and White patients should be considered when tailoring induction regimens to improve outcomes of all patients and bridge the racial disparity gap ...
Young Women With Breast Cancer: Discussing vs Pursuing Fertility Preservation
In 2023, nearly 300,000 new cases of invasive breast cancer were diagnosed in the United States, and approximately 56,000 new cases of ductal carcinoma in situ were diagnosed. Although most of those cancers are diagnosed in older adults, about 9% of all new cases of breast cancer are found in women ...
Genetic Identification of Women at Lower Risk of Breast Cancer
In a retrospective analysis reported in JAMA Oncology, Bolze et al identified a group of women at low risk for breast cancer based on genetic analysis. The findings may support altering cancer screening in this low-risk group. As stated by the investigators, “Genetic information is not being used...
Novel Risk Model May Personalize Prognosis Prediction in Patients With Multiple Myeloma
Researchers have developed a novel computational model for personalized prognosis prediction in patients with newly diagnosed multiple myeloma, according to a new study published by Maura et al in the Journal of Clinical Oncology. Their model for individualized risk in multiple myeloma, or IRMMa,...
ACRO, ACR, ASTRO, and ASCO Unite to Ensure Patient Access to Quality Cancer Care
The American College of Radiation Oncology (ACRO), the American College of Radiology (ACR), the American Society for Radiation Oncology (ASTRO), and ASCO—some of the largest professional societies representing radiation oncology physicians in the United States—announced a new partnership to reform...
Medical Cannabis: Patterns of Use Among Patients With Cancer
Guest Editor’s Note: Cannabis products are rising in popularity and increasingly used for medical purposes. For appropriate counseling and guidance in an oncology setting, clinicians must understand current cannabis use patterns among patients with cancer. In this article, Nirupa Raghunathan, MD,...
ALL in Adults: Trial Updates and Clinical Considerations for Selecting Consolidation Therapy
Although pediatric patients with acute lymphoblastic leukemia (ALL) have seen a dramatic improvement in long-term survival rates over the past 40 years, from approximately 10% to over 95%, adults aged 29 and older have not experienced the same treatment benefits, with survival rates still below...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
Addition of MRI to CT in Patients Scheduled for Colorectal Liver Metastases Local Therapy
In the European CAMINO study reported in The Lancet Oncology, Görgec et al identified the likelihood of change in treatment plans with the addition of contrast-enhanced magnetic resonance imaging (MRI) in patients scheduled for local therapy for colorectal liver metastases on the basis of...
Call to Action Issued to Expand Access to Clinical Trials
A paper published by Harvey et al in the journal Cancer detailed three calls to action that the oncology research and clinical care communities should implement to expand access to clinical trials and improve inclusivity to enable more people with cancer to participate in trials closer to home. The ...
Novel Vaccine May Delay Relapse in KRAS-Mutated Pancreatic and Colorectal Cancers
A novel vaccine may be effective at preventing relapse in patients with KRAS-mutated pancreatic and colorectal cancers, according to a recent study published by Pant et al in Nature Medicine. Background KRAS-mutated cancers make up about 25% of all solid tumors, including 90% of pancreatic cancer...
Attitudes Toward Climate Change May Impact Cancer Screening Behavior
Investigators have discovered that individuals who view climate change as a health threat may be more likely to undergo cancer screening, according to a recent study published by Qian et al in the Journal of the National Cancer Institute. The recent findings supported the development of public...
Atezolizumab Plus Carboplatin in Metastatic Triple-Negative Breast Cancer
Researchers have evaluated the efficacy of atezolizumab in combination with carboplatin in patients with triple-negative breast cancer, according to a recent study published by Lehmann et al in JAMA Oncology. The new findings may help researchers better understand biomarkers of immunotherapy...
Real-World Data Show Impact of Immunotherapy in Populations Underrepresented in Lung Cancer Clinical Trials
New research published by Lee et al in JNCCN—Journal of the National Comprehensive Cancer Network found patients treated with first-line immunotherapy for advanced non–small cell lung cancer (NSCLC) had similar results in terms of overall survival, progression-free survival, and treatment duration, ...
Expert Point of View: Carlos L. Arteaga, MD
Carlos L. Arteaga, MD, commented on the findings of the PREFERABLE-EFFECT trial: “This is a wonderful study about what has been obvious to all of us—exercise improves quality of life. Most oncologists probably recommend it, but not necessarily in the structured and rigorous way this study did. We...
Patients With Advanced Breast Cancer May Gain Multiple Benefits From Exercise as Part of Palliative Care
Although current ASCO guidelines recommend exercise for patients with breast cancer during adjuvant therapy with curative intent, the guidelines state that more study is needed regarding the effects of exercise for patients with metastatic breast cancer. The results of the PREFERABLE-EFFECT trial...
Triple-Negative Breast Cancer: Several Treatment Response Trajectories Identified
Investigators analyzed cells within triple-negative breast cancers before and after radiation therapy combined with pembrolizumab and identified three patient groups with different responses to the treatment. Their study, published by Shiao et al in Cancer Cell, found that for some patients with...
Non–Locally Advanced Rectal Cancer: Impact of Reduced Use of Neoadjuvant Radiotherapy
In a Dutch nationwide cross-sectional cohort study reported in JAMA Oncology, Hazen et al found that a reduced use of neoadjuvant radiotherapy as part of chemoradiotherapy was not associated with poorer outcomes in patients with non–locally advanced rectal cancer. As stated by the investigators,...
Long-Term Results With Front-Line Dasatinib/Blinatumomab for Philadelphia Chromosome–Positive ALL
As reported in the Journal of Clinical Oncology by Foà et al, long-term results of the Italian D-ALBA study have shown that a chemotherapy-free induction/consolidation regimen of dasatinib followed by blinatumomab maintained highly favorable outcomes in the front-line treatment of adult patients...
Lapatinib Increases Overall Survival in Patients With Metastatic Breast Cancer and HER2-Positive CTCs
A recent study showed that the HER2-targeted tyrosine kinase inhibitor lapatinib was associated with improved overall survival in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells (CTCs). These findings were published by Fehm et al in Clinical...
Baseline Estradiol and Prevention of Breast Cancer in High-Risk Postmenopausal Women
In an analysis from the IBIS-II prevention trial reported in The Lancet Oncology, Jack Cuzick, PhD, and colleagues found that increasing the ratio of baseline estradiol level to sex hormone–binding globulin (SHBG) was associated with an increased risk of breast cancer in high-risk postmenopausal...
Treatment at Community Cancer Centers May Be Linked to Poorer Outcomes in Patients With HPV-Related Oropharyngeal Squamous Cell Carcinoma
Treatment in community cancer centers may be associated with a lower rate of survival among patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma of the oropharynx, according to a recent study published by Trakimas et al in the Journal of the National Cancer...
Antibody-Drug Conjugate Ifinatamab Deruxtecan Shows Robust Activity in Refractory Small Cell Lung Cancer
The antibody-drug conjugate ifinatamab deruxtecan has demonstrated “robust and durable efficacy” in patients with heavily pretreated small cell lung cancer, according to a subset analysis of the DS7300-A-J101 trial presented at the International Association for the Study of Lung Cancer 2023 World...
Next-Generation Sequencing May Help Improve Access to Immunotherapy Among Patients With Cancer and Mismatch Repair Deficiency
Next-generation sequencing may help better identify patients with cancer and mismatch repair deficiency who may benefit from immunotherapy, according to a recent study published by Farhat et al in Cancer Cell. The new findings indicated that treating more patients with immunotherapy may require...
How Being a Member of the President’s National Cancer Advisory Board Is Contributing to High-Quality Oncology Care
This past year, President Joe Biden announced the appointment of six members to the National Cancer Advisory Board (NCAB; see related article). This board plays a crucial role in advising and assisting the director of the National Cancer Institute (NCI) in setting the activities of the national...
Can Immunotherapy Induce Sustained Disease Control Among Patients With Colorectal Cancer?
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States, and the third-leading cause of cancer-related deaths. According to the American Cancer Society, in 2023, it is estimated that about 52,550 individuals died from the...
Incidence of Second Primary Cancers in Adult Cancer Survivors
In a Danish population-based retrospective cohort study reported in The Lancet Oncology, Kjaer et al identified the cumulative incidence of second primary cancers among cancer survivors aged ≥ 40 years who were alive 1 year after diagnosis. Study Details The study involved data from 457,334...
Immune Checkpoint Inhibitor–Induced Myocarditis: Contemporary Retrospective Analysis
In a retrospective cohort study of 160 patients with cancer who were suspected of having immune checkpoint inhibitor (ICI)-induced myocarditis, published in JACC: CardioOncology, Osnat Itzhaki Ben Zadok, MD, MSc, and colleagues found that severe ICI-induced myocarditis seemed to be linked to...
Novel Antibody-Drug Conjugate Under Study in Treatment of Gastric or Gastroesophageal Junction Cancers
A first-in-class, claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate may prove to be an effective treatment option for patients with advanced gastric or gastroesophageal junction cancer, according to data presented during the ASCO Plenary Series: November 2023.1 (The ASCO Plenary Series is...
ASCO and Ontario Health Publish New Recommendations for Systemic Therapy in SCLC
A newly published guideline update from ASCO and Ontario Health provides evidence-based recommendations on the use of systemic therapy for small cell lung cancer (SCLC).1 Recommendations cover where novel agents fit in the treatment landscape, the management of disease in older patients with...
Improving Cancer Control in a Changing World
On October 16 and 17, 2023, the Union for International Cancer Control (UICC) welcomed more than 350 attendees from over 75 countries to its World Cancer Leaders’ Summit in Long Beach, California, to discuss some of the most challenging issues facing patients with cancer worldwide. The theme of...
LuPSMA: Another Treatment Option for Metastatic Castration-Resistant Prostate Cancer
The use of lutetium-177–labeled PSMA-617 (LuPSMA) improved radiographic progression–free survival by 57% in men with metastatic castration-resistant prostate cancer who experienced disease progression on an androgen receptor (AR) pathway inhibitor compared with changing to a new AR pathway...
I Don’t Want Cancer to Define Me
Except for a series of unexplained multiple broken bones and inexplicable excruciating pain in my right hip and leg, I had no other hallmarks of multiple myeloma when I was diagnosed with the disease at age 48 in 2014. My blood test values were all normal, and I didn’t have anemia or kidney damage. ...
New Findings Challenge Widely Accepted Beliefs About the Relative Efficacy of Opioids in Treating Cancer Pain
Investigators have uncovered concerningly large gaps in evidence regarding the true benefits of opioids for pain relief in patients with cancer, according to a novel study published by Shaheed et al in CA: A Cancer Journal for Clinicians. The new findings could challenge the commonly held view that ...
Community Program Cuts Treatment Delays in Half for Minority and Low-Income Patients
A program aimed at improving access to high-quality cancer care has significantly increased adherence to cancer treatment among minority and low-income communities, according to data presented at the 2023 ASCO Quality Care Symposium.1 The introduction of the ALCANCE-PLUS program in Monterey County, ...
Overcoming BPDCN: Tagraxofusp Sets New Landmark in Patient Survival
A novel first-in-class therapy may help to redefine survival expectations for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data presented at the 2023 ASH Annual Meeting & Exposition (Abstract 547). Results of a European named-patient program study showed...
All Adult Oncologists Are Geriatric Oncologists
The data developed over the past few years have overwhelmingly favored geriatric assessment as part of the routine care for older patients with cancer. It has become the standard of care. ASCO has recently published a Practical Geriatric Assessment to aid in the implementation of this vital...
Cardiovascular Health of Women Treated for Cancer: Understanding the Long-Term Risks
At the 2023 Global Cardio-Oncology Summit in Madrid, in a joint session with ASCO and the International Cardio-Oncology Society, Anita Arnold, DO, FACC, MBA, Director, Noninvasive Cardiology, and Director of Cardio-Oncology, Lee Memorial Health Systems, Fort Myers, Florida, discussed the...
Advanced NSCLC: Adding Canakinumab to First-Line Chemoimmunotherapy
As reported in the Journal of Clinical Oncology by Tan et al, the phase III CANOPY-1 trial has shown no survival benefits with the addition of canakinumab to first-line pembrolizumab plus chemotherapy in patients with advanced/metastatic non–small cell lung cancer (NSCLC) without EGFR or ALK...
